1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: generic
Jagsonpal Pharmaceuticals Ltd.

Jagsonpal Pharmaceuticals Ltd.

211.76
INR
+0.90
(+0.43%)
6.67EPS
35.14P/E
15.68BMarket Cap
Jagsonpal Pharmaceuticals Ltd.
NSE:JAGSNPHARM
(National Stock Exchange of India)

Recent

price

211.76

P/E

ratio

35.14

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
24.58
26.95
25.42
21.98
21.09
21.91
21.97
19.32
25.47
24.21
28.69
33.22
36.14
31.56
40.11
42.66
43.78
Revenue per Share
1.1
1.14
0.28
0.32
0.18
0.5
1.81
-1.76
1.1
1.2
2.6
2.88
4.08
3.4
8.26
6.4
6.77
Basic EPS, GAAP
-0.31
1.08
1.84
1.15
0.66
1.38
-0.89
-0.24
4.72
1.81
4.31
0.9
7.07
5.28
8.17
6.93
- -
Free Cash Flow per Basic Share
0.2
0.2
0.2
0.2
0.04
0.04
0.04
0.04
0.1
0.2
0.4
1.6
- -
1.98
1.97
2.47
- -
Dividend per Share
14.19
15.03
15.02
15.05
14.09
15.02
16.78
14.97
15.95
16.95
19.07
20.27
24.26
28.35
36.14
41.24
- -
Book Value per Share
14.18
15.03
15.02
15.05
14.09
15.01
16.78
14.65
15.63
16.59
19.06
20.27
24.26
28.35
23.24
29.6
- -
Tangible Book Value per Share
65
65
65
65
65
65
65
65
65
65
65
65
65
66
67
67
67
Basic Weighted Avg Shares
1,610
1,765
1,665
1,439
1,382
1,435
1,439
1,265
1,668
1,586
1,879
2,176
2,367
2,087
2,687
2,872
2,938
Sales/Revenue/Turnover
7.66
7.98
4.41
5.5
4.43
6.49
2.86
-8.94
5.07
4.67
10
11.28
14.5
10.35
15.98
16.93
17.65
Operating Margin (%)
22
25
27
28
27
31
20
11
10
11
11
15
12
17
81
94
92
Depreciation Expense
72
75
18
21
12
33
119
-116
72
79
171
189
267
225
554
431
455
Net Income, GAAP
22.53
26.1
27.74
16.22
29.95
20.15
17.59
- -
19.85
16.4
22.01
29.23
23.23
24.79
20.75
25.1
25.16
Effective Tax Rate (%)
4.46
4.22
1.1
1.47
0.85
2.27
8.25
-9.13
4.33
4.96
9.08
8.67
11.29
10.76
20.6
15
15.48
Profit Margin (%)
357
376
364
377
406
436
807
660
694
617
810
821
1,370
1,777
1,353
1,148
- -
Working Capital
3
3
3
- -
- -
- -
- -
- -
- -
- -
- -
- -
52
76
76
66
- -
LT Debt
929
985
984
986
954
984
1,099
980
1,045
1,110
1,249
1,328
1,589
1,874
2,400
2,762
- -
Total Equity
6.26
5.67
1.22
1.59
0.87
2.4
9.11
- -
5.92
5.08
11.18
12.61
15.72
9.04
22.37
13.09
- -
Return on Invested Capital (%)
8.5
5.85
1.38
4.98
3.02
5.4
10.92
- -
7.06
7.26
13.96
14.4
18.1
12.76
25.16
16.38
- -
Return on Capital (%)
7.96
7.79
1.86
2.15
1.21
3.36
11.39
-11.11
7.13
7.3
14.46
14.64
18.32
12.97
25.91
16.69
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
16
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
66
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
67
67
66
Market Capitalization
12,863
12,323
15,675

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
1,431
- -
Cash, Cash Equivalents & STI
- -
1,061
- -
Accounts Receivable, Net
- -
172
- -
Inventories
- -
146
- -
Total Current Liabilities
- -
283
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
16
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.33%
17.41%
15.1%
Free Cash Flow
-159.38%
125.65%
-14.79%
Net Income, GAAP
19.12%
32.12%
-22.18%
Sales/Revenue/Turnover
8.2%
9.68%
6.89%
Total Cash Common Dividend
- -
- -
25.92%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
614
747
740
586
2,687
2026
756
745
729
642
2,872
2027
822
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.78
1.72
4.74
0.98
8.26
2026
1.6
1.88
1.67
1.25
6.4
2027
2
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
1.97
2026
- -
- -
- -
- -
2.47
2027
- -
- -
- -
- -
- -
Similar Companies
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Teva Pharmaceutical Industries Limited (TASE:TEVA)
Zim Laboratories Ltd. (NSE:ZIMLAB)
Paradigm Biopharmaceuticals Ltd. (ASX:PAR)
Neuren Pharmaceuticals Limited (ASX:NEU)
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A (TWSE:1762)
Business
Jagsonpal Pharmaceuticals Limited manufactures, sells and trades pharmaceutical formulations and active pharmaceutical ingredients in India and internationally. The company offers products in gynaecology, orthopaedics, dermatology, paediatrics, antibiotics, allergy management, immunity and cell protection, OTC products; formulations include tablets, softgels, injections, capsules and syrups such as Maintane, Metabolin, Parvon, Rowezy and Queezy; it maintains 17 brands among the top five in their molecule categories, with top five brands contributing about 47% and top seven about 67% of revenues. Founded in 1978 and headquartered in New Delhi, India, Jagsonpal operates through a sales team of over 900 personnel with a pan-India presence and serves healthcare professionals and government institutions. In 2024, the company acquired the India and Bhutan businesses of Yash Pharma, integrating 33 established brands in dermatology and paediatrics to expand into a market segment valued at INR 20,000 crore and enhance therapeutic reach. It recently appointed a chief operating officer and chief financial officer, reported half-year revenue of INR 150.1 million and PAT of INR 234 million for FY26 with 10.2% and 39.2% year-over-year growth respectively, and sustains strong profit growth of 38.2% CAGR over five years while remaining nearly debt-free.